**PATENT** 

## E UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sheng C. Lou, et al.

Serial No.: 09/731,126

Filed: December 6, 2000

Title: MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS

ANDUSES THEREOF

Attorney Docket No.: 6755.US.01

Examiner: (not yet assigned)

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclose being deposited with the United States Posta Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents Washington, D.C. 20231, on:

growing a.

2-3-0=

nberly A. florio Date

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Documents listed in this Supplemental Information Disclosure Statement, were first cited in a communication from a Foreign Patent Office by the European Patent Office in a counterpart international PCT application No. PCT/US01/43179. This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Reference DE19727943 is not in the English language; therefore, Applicants submit herein the English version of the abstract of corresponding International Patent WO 98/40744. If the Examiner further requires a full translation, please contact the undersigned.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

USSN: 09/731,126 Attorney Docket No.: 6755.US.01 Information Disclosure Statement Page 2

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants believe no charge is required for the submission of this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 (b). However, if a fee is determined to be due, the Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES Telephone: (847) 935-1729

Facsimile: (847) 938-2623

Respectfully submitted, Sheng C. Lou, et al.

Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants

DATE: February 3, 2003 SHEET \_1\_ of \_1\_

## Form PTO - 1449 (Modified)

FORM PTO-1 (Modified)	449 U.S		ATTY. DOCKET NO.			SERIAL NO.					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)					6755.US.01			09/73	09/731,126		
					APPLICANT(S) Sheng C. Lou, et al.						
											FILING DATE
					December 6, 2000			1645	1645		
					(37 CFR 1.98 (	b))					
U.S.PATENT DOCUMENTS											
EXAMINER			ISSUE					SUB			
INITIAL	A1	PATENT NUMBER 5612453 A	DATE 03/18/1997		VENTOR	CLASS	CLASS		DATE		
	AI	3012433 A	03/18/1997	Wolf Hans, et al.							
	İ					ĺ					
				ļ			<b>.</b>				
				<u> </u>							
	-			<u> </u>							
	ŀ					i					
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION										•	
		DOCUMENT	PUBLIC-ATION	1 -	OUNTRY OR CLASS TENT OFFICE		ASS	SUB TRANS			
		NUMBER	DATE	PA				CLASS	LATION YES NO		
-	B1	9014358 A	11/29/1990	PC7					IES	I	
· · · · · · · · · · · · · · · · · · ·	B2	034561 A	12/13/1989	EPC	)				<del>                                     </del>	1	
	В3	19727943	09/24/1998	DE							
-	B4	9840744 /	09/17/1998	PCT	Abstract						
		OTHER DOCUM	ENTS (Includio	ng Auth	or Title Da	te Place of	Publ	ication)			
	OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  C1 Niedrig, M. et al., "Characterization of Murine Monoclonal Antibodies Directed Against the core										
		Proteins of Human Immunodeficiency Virus Types 1 and 2, "Journal of Virology, 65/8:4529-4533 (1991)									
	C2	Minassian, A.A, et al., "Monoclonal Antibodies Against Human Immunodeficiency Virus HIV									
		Type 2 Core Proteins Cross-Reactivity With HIV Type 1 and Simian Immunodeficiency Virus,"  Proceedings of the national Academy of Sciences of the Haited States (1/8/6020 (0.42/1088))									
	C3	Proceedings of the national Academy of Sciences of the United States, 6/18:6939-6943 (1988)  Zolla-Pazner, Susan, et al., "The Implication of Antigenic Diversity for Vaccine Development,"									
		Immunology Letters, 66/1-3: 159-164 (1999-03)									
						<del></del> -					
EXAMINER					ATE CONSIDERED						
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and											
not considered. Include copy of this form with next communication to applicant.											